{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:58:39Z","timestamp":1780574319528,"version":"3.54.1"},"reference-count":146,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.xjidi.2021.100042","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T23:38:52Z","timestamp":1627601932000},"page":"100042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0976-4982","authenticated-orcid":false,"given":"Masahiro","family":"Kamata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3743-135X","authenticated-orcid":false,"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2021.100042_bib1","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jaip.2020.09.042","article-title":"Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis","volume":"9","author":"Achten","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.xjidi.2021.100042_bib2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib3","first-page":"79","article-title":"Dupilumab side effect in a patient with atopic dermatitis: a case report study","volume":"13","author":"Albader","year":"2019","journal-title":"Biologics"},{"key":"10.1016\/j.xjidi.2021.100042_bib4","first-page":"804","article-title":"Efficacy of dupilumab in different racial subgroups of adults with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials","volume":"18","author":"Alexis","year":"2019","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2016.08.047","article-title":"Autoimmune diseases in adults with atopic dermatitis","volume":"76","author":"Andersen","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/all.14080","article-title":"Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry","volume":"75","author":"Ari\u00ebns","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.xjidi.2021.100042_bib7","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jaad.2020.08.127","article-title":"Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-week results from the Dutch BioDay registry","volume":"84","author":"Ari\u00ebns","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib8","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/1346-8138.14218","article-title":"Burden of atopic dermatitis in Japanese adults: analysis of data from the 2013 National Health and Wellness Survey","volume":"45","author":"Arima","year":"2018","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib9","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/bjd.18041","article-title":"Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series","volume":"181","author":"Armario-Hita","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.xjidi.2021.100042_bib11","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/bjd.17538","article-title":"Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis","volume":"180","author":"Bakker","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abe2749","article-title":"Persistence of mature dendritic cells, TH2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4R\u03b1 blockade","volume":"6","author":"Bangert","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.xjidi.2021.100042_bib13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ajoc.2017.06.017","article-title":"Cicatricial ectropion in a patient treated with dupilumab","volume":"7","author":"Barnes","year":"2017","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.xjidi.2021.100042_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1167\/tvst.9.3.29","article-title":"Dupilumab-associated mucin deficiency (DAMD) [published correction appears in Transl Vis Sci Technol 2020;9:21]","volume":"9","author":"Barnett","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.xjidi.2021.100042_bib15","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40257-020-00527-x","article-title":"Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis","volume":"21","author":"Beck","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib16","first-page":"1","article-title":"Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study","author":"Beck","year":"2021","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.xjidi.2021.100042_bib17","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2021.100042_bib18","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/jdv.16948","article-title":"Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials","volume":"35","author":"Bieber","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2021.100042_bib19","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2021.100042_bib20","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jaip.2020.12.059","article-title":"Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis","volume":"9","author":"Boguniewicz","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.xjidi.2021.100042_bib21","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/ICO.0000000000002461","article-title":"Dupilumab-associated ocular surface disease: clinical characteristics, treatment, and follow-up","volume":"40","author":"Bohner","year":"2021","journal-title":"Cornea"},{"key":"10.1016\/j.xjidi.2021.100042_bib22","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/rheumatology\/keaa568","article-title":"Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy","volume":"60","author":"Bridgewood","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.xjidi.2021.100042_bib23","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ad.2013.02.005","article-title":"Immunogenicity in biologic therapy: implications for dermatology","volume":"104","author":"Carrascosa","year":"2013","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.xjidi.2021.100042_bib24","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2021.100042_bib25","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2340\/00015555-3208","article-title":"Diagnosis of mycosis fungoides following administration of dupilumab for misdiagnosed atopic dermatitis","volume":"99","author":"Chiba","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.xjidi.2021.100042_bib26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.anai.2021.03.019","article-title":"Clinical phenotyping of atopic dermatitis using combined itch and lesional severity: a prospective observational study","volume":"127","author":"Chovatiya","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.xjidi.2021.100042_bib27","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1080\/09546634.2019.1612836","article-title":"Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2","volume":"31","author":"Cork","year":"2020","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.xjidi.2021.100042_bib28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/bjd.18476","article-title":"Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension","volume":"182","author":"Cork","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib29","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/bjd.19460","article-title":"Dupilumab provides favourable long-term safety and efficacy in children aged \u2265 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study","volume":"184","author":"Cork","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.xjidi.2021.100042_bib31","doi-asserted-by":"crossref","first-page":"e13979","DOI":"10.1111\/dth.13979","article-title":"Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients","volume":"33","author":"Dal Bello","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.xjidi.2021.100042_bib32","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jdcr.2019.07.020","article-title":"Dupilumab facial redness: positive effect of itraconazole","volume":"5","author":"de Beer","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.xjidi.2021.100042_bib33","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/bjd.16348","article-title":"Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with demodex and increased interleukin-17 levels?: reply from the authors","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib34","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib35","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjd.18179","article-title":"Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data","volume":"182","author":"de Wijs","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib36","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjd.18730","article-title":"Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series","volume":"183","author":"de Wijs","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib37","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/ced.14050","article-title":"Acute arthritis and arthralgia as an adverse drug reaction to dupilumab","volume":"45","author":"de Wijs","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib39","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jaad.2019.03.037","article-title":"Burden of illness in adults with atopic dermatitis: analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom","volume":"81","author":"Eckert","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","article-title":"Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort","volume":"81","author":"Faiz","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib42","article-title":"A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis [e-pub ahead of print]","author":"Fargnoli","year":"2020","journal-title":"J\u00a0Dermatol Treat"},{"key":"10.1016\/j.xjidi.2021.100042_bib41","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/09546634.2019.1682503","article-title":"Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis","volume":"32","author":"Fargnoli","year":"2019","journal-title":"J\u00a0Dermatol Treat"},{"key":"10.1016\/j.xjidi.2021.100042_bib43","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-2-3","article-title":"Conjunctivitis in patients with atopic dermatitis treated with dupilumab","volume":"9","author":"Ferreira","year":"2020","journal-title":"Drugs Context"},{"key":"10.1016\/j.xjidi.2021.100042_bib44","first-page":"791","article-title":"Clinical response and quality of life in patients with severe atopic dermatitis treated with dupilumab: a single-center real-life experience","volume":"9","author":"Ferrucci","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.xjidi.2021.100042_bib45","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2017.09.052","article-title":"Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials","volume":"78","author":"Fleming","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib46","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/DER.0000000000000481","article-title":"Psoriasiform dermatitis after initiation of treatment with dupilumab for atopic dermatitis","volume":"30","author":"Fowler","year":"2019","journal-title":"Dermatitis"},{"key":"10.1016\/j.xjidi.2021.100042_bib47","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/sextrans-2016-052811","article-title":"Herpes simplex virus specific T cell response in a cohort with primary genital infection correlates inversely with frequency of subsequent recurrences","volume":"93","author":"Franzen-R\u00f6hl","year":"2017","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.xjidi.2021.100042_bib48","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2249.1995.tb03796.x","article-title":"Measurement of IL-4 in tears of patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis","volume":"102","author":"Fujishima","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.xjidi.2021.100042_bib49","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/1203475417743233","article-title":"Diagnosis and management of conjunctivitis for the dermatologist","volume":"22","author":"Gooderham","year":"2018","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.xjidi.2021.100042_bib50","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2021.100042_bib51","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib52","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/bjd.18976","article-title":"The effectiveness of dupilumab in patients with alopecia areata who have atopic dermatitis: a case series of seven patients","volume":"183","author":"Harada","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib53","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/09546634.2019.1624683","article-title":"Rosacea associated with dupilumab therapy","volume":"32","author":"Heibel","year":"2021","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.xjidi.2021.100042_bib54","doi-asserted-by":"crossref","first-page":"e12762","DOI":"10.1111\/dth.12762","article-title":"New alcohol flushing in a patient with atopic dermatitis under therapy with dupilumab","volume":"32","author":"Herz","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.xjidi.2021.100042_bib55","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.xjidi.2021.100042_bib56","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.jaci.2005.12.1345","article-title":"Cathelicidin deficiency predisposes to eczema herpeticum","volume":"117","author":"Howell","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2021.100042_bib57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jdcr.2019.12.002","article-title":"Alcohol-induced facial flushing in a patient with atopic dermatitis treated with dupilumab","volume":"6","author":"Igelman","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.xjidi.2021.100042_bib58","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1111\/jdv.16239","article-title":"Polyenthesitis during treatment with dupilumab for atopic dermatitis","volume":"34","author":"Ishibashi","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2021.100042_bib59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jdin.2020.06.004","article-title":"Introduction of self-injection increases compliance with dupilumab administration in adult patients with atopic dermatitis: a single-center retrospective study","volume":"1","author":"Ito","year":"2020","journal-title":"JAAD Int"},{"key":"10.1016\/j.xjidi.2021.100042_bib60","first-page":"280","article-title":"How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations","volume":"25","author":"Jahn","year":"2009","journal-title":"N\u00a0Biotechnol"},{"key":"10.1016\/j.xjidi.2021.100042_bib61","first-page":"1982","article-title":"Retrospective study of dupilumab treatment for moderate to severe atopic dermatitis in Korea: efficacy and safety of dupilumab in real-world practice","volume":"9","author":"Jang","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.xjidi.2021.100042_bib62","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jaad.2021.01.012","article-title":"Facial and neck erythema associated with dupilumab treatment: a systematic review","volume":"84","author":"Jo","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib63","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.jaad.2020.02.029","article-title":"Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: a retrospective cohort study","volume":"82","author":"Jo","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib64","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1177\/1203475420928907","article-title":"Short-term evaluation of the real-world efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis: a Canadian multicenter retrospective cohort study [Formula: see text]","volume":"24","author":"Jo","year":"2020","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.xjidi.2021.100042_bib65","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1111\/1346-8138.14880","article-title":"Case of alopecia areata during\u00a0dupilumab treatment for atopic dermatitis","volume":"46","author":"Kanda","year":"2019","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib66","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/1346-8138.15464","article-title":"Higher baseline serum lactate dehydrogenase level is associated with poor effectiveness of dupilumab in the long term in patients with atopic dermatitis","volume":"47","author":"Kato","year":"2020","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib67","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjd.18565","article-title":"Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials","volume":"183","author":"Katoh","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib68","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1038\/jid.2013.223","article-title":"IL-25 enhances HSV-1 replication by inhibiting filaggrin expression, and acts synergistically with Th2 cytokines to enhance HSV-1 replication","volume":"133","author":"Kim","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib69","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1111\/ijd.15053","article-title":"Real-world experience of dupilumab in the treatment of moderate-to-severe atopic dermatitis","volume":"59","author":"Kim","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib70","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1111\/1346-8138.15872","article-title":"Arthritis and enthesitis during dupilumab therapy completely remitted by celecoxib","volume":"48","author":"Komaki","year":"2021","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib71","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s13555-020-00469-6","article-title":"Real-world experience and laboratory monitoring of dupilumab in patients with moderate to severe atopic dermatitis in a tertiary centre","volume":"11","author":"Kreeshan","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.xjidi.2021.100042_bib72","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jid.2017.01.030","article-title":"Increased risk of cutaneous and systemic infections in atopic dermatitis-a cohort study","volume":"137","author":"Langan","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib73","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3576","article-title":"Dupilumab treatment in two patients with cutaneous T-cell lymphomas","volume":"100","author":"Lazaridou","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.xjidi.2021.100042_bib74","doi-asserted-by":"crossref","first-page":"100848","DOI":"10.1016\/j.ajoc.2020.100848","article-title":"Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis","volume":"19","author":"Li","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.xjidi.2021.100042_bib75","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/ICO.0000000000002262","article-title":"Dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"39","author":"Liberman","year":"2020","journal-title":"Cornea"},{"key":"10.1016\/j.xjidi.2021.100042_bib76","doi-asserted-by":"crossref","first-page":"e12869","DOI":"10.1111\/dth.12869","article-title":"Development of alopecia in patients treated with dupilumab","volume":"32","author":"Maloney","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.xjidi.2021.100042_bib77","article-title":"Cause or cure? Review of dupilumab and alopecia areata [e-pub ahead of print]","author":"Marks","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib78","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1111\/jdv.14387","article-title":"Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients","volume":"31","author":"Masson Regnault","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2021.100042_bib79","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/cia2.12099","article-title":"Real-world use of dupilumab for 53 patients with atopic dermatitis in Japan","volume":"3","author":"Matsutani","year":"2020","journal-title":"J\u00a0Cutan Immunol Allergy"},{"key":"10.1016\/j.xjidi.2021.100042_bib80","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamadermatol.2014.3324","article-title":"Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis","volume":"151","author":"Mohan","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib81","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/bjophthalmol-2019-315010","article-title":"Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment","volume":"104","author":"Nahum","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xjidi.2021.100042_bib82","doi-asserted-by":"crossref","first-page":"e22043","DOI":"10.1097\/MD.0000000000022043","article-title":"Exploration of biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab: a study protocol","volume":"99","author":"Nakahara","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.xjidi.2021.100042_bib83","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.alit.2020.07.001","article-title":"Dupilumab-resistant facial erythema - dermoscopic, histological and clinical findings of three patients","volume":"70","author":"Nakanishi","year":"2021","journal-title":"Allergol Int"},{"key":"10.1016\/j.xjidi.2021.100042_bib84","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/bjd.19459","article-title":"Increased expression of interleukin-23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment","volume":"184","author":"Napolitano","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib85","doi-asserted-by":"crossref","first-page":"e13142","DOI":"10.1111\/dth.13142","article-title":"Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: a case series","volume":"32","author":"Napolitano","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.xjidi.2021.100042_bib86","doi-asserted-by":"crossref","first-page":"201","DOI":"10.18176\/jiaci.0481","article-title":"Dupilumab-associated conjunctivitis in patients with atopic dermatitis: a multicenter real-life experience","volume":"30","author":"Nettis","year":"2020","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.xjidi.2021.100042_bib87","article-title":"Use of dupilumab for 543 adult patients with moderate-to-severe atopic dermatitis: a multicenter, retrospective study [e-pub ahead of print]","author":"Nettis","year":"2020","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.xjidi.2021.100042_bib88","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1111\/all.14338","article-title":"Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis","volume":"75","author":"Nettis","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.xjidi.2021.100042_bib89","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.5070\/D3271052041","article-title":"Two cases of mycosis fungoides diagnosed after treatment non-response to dupilumab","volume":"27","author":"Newsom","year":"2021","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.xjidi.2021.100042_bib90","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2021.100042_bib91","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1111\/jdv.16383","article-title":"Successful topical treatment with ketoconazole for facial rashes refractory to dupilumab in patients with atopic dermatitis: case reports","volume":"34","author":"Okiyama","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2021.100042_bib92","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jdv.15609","article-title":"Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre","volume":"33","author":"Olesen","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2021.100042_bib93","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","volume":"83","author":"Paller","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib94","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40257-021-00597-5","article-title":"Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study","volume":"22","author":"Patruno","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib95","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/jdv.17094","article-title":"Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study","volume":"35","author":"Patruno","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2021.100042_bib96","doi-asserted-by":"crossref","first-page":"100550","DOI":"10.1016\/j.ajoc.2019.100550","article-title":"Dupilumab-associated blepharoconjunctivitis","volume":"16","author":"Paulose","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.xjidi.2021.100042_bib97","doi-asserted-by":"crossref","DOI":"10.1038\/s41433-020-01379-9","article-title":"Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae [e-pub ahead of print]","author":"Popiela","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xjidi.2021.100042_bib98","first-page":"1241","article-title":"Dupilumab for the treatment of atopic dermatitis in an Austrian cohort-real-life data shows rosacea-like folliculitis","volume":"9","author":"Quint","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.xjidi.2021.100042_bib99","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2021.100042_bib100","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2021.100042_bib101","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/14712598.2016.1188076","article-title":"A\u00a0novel therapeutic paradigm for patients with extensive alopecia areata","volume":"16","author":"Renert-Yuval","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.xjidi.2021.100042_bib102","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1111\/jdv.16219","article-title":"Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: a real-life Italian tertiary centre experience","volume":"34","author":"Ribero","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2021.100042_bib103","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1111\/jdv.15118","article-title":"Dupilumab: short-term effectiveness and security in real clinical practice - a retrospective multicentric study","volume":"33","author":"Ruiz-Villaverde","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2021.100042_bib104","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/1203475421995186","article-title":"Alopecia areata related paradoxical reactions in patients on dupilumab therapy: a systematic review [published correction appears in J Cutan Med Surg 2021;25:464]","volume":"25","author":"Sachdeva","year":"2021","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.xjidi.2021.100042_bib105","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/rheumatology\/kev277","article-title":"Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice","volume":"55","author":"Schaeverbeke","year":"2016","journal-title":"Rheumatolpgy (Oxford)"},{"key":"10.1016\/j.xjidi.2021.100042_bib106","first-page":"e7831","article-title":"Clinical psoriasiform dermatitis following dupilumab use for autoeczematization secondary to chronic stasis dermatitis","volume":"12","author":"Schrom","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.xjidi.2021.100042_bib107","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bjd.19631","article-title":"Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single-centre, prospective 1-year observational cohort study of the first 100 patients treated","volume":"184","author":"Sears","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib108","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.4168\/aair.2020.12.6.1063","article-title":"Facial redness in atopic dermatitis patients treated with dupilumab: a case series","volume":"12","author":"Seok","year":"2020","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.xjidi.2021.100042_bib109","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","article-title":"Comorbidities and the impact of atopic dermatitis","volume":"123","author":"Silverberg","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.xjidi.2021.100042_bib110","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.mcna.2019.08.009","article-title":"Atopic dermatitis in adults","volume":"104","author":"Silverberg","year":"2020","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.xjidi.2021.100042_bib111","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.anai.2020.07.026","article-title":"Real-world persistence with dupilumab among adults with atopic dermatitis","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.xjidi.2021.100042_bib112","article-title":"Dupilumab significantly modulates pain and discomfort in patients with atopic dermatitis: a post hoc analysis of 5 randomized clinical trials [e-pub ahead of print]","author":"Silverberg","year":"2020","journal-title":"Dermatitis"},{"key":"10.1016\/j.xjidi.2021.100042_bib113","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.17351","article-title":"Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis [e-pub ahead of print]","author":"Silverberg","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2021.100042_bib114","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13671-011-0003-5","article-title":"Comorbidity in atopic dermatitis","volume":"1","author":"Simpson","year":"2012","journal-title":"Curr Dermatol Rep"},{"key":"10.1016\/j.xjidi.2021.100042_bib115","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","article-title":"Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults","volume":"74","author":"Simpson","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib116","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2021.100042_bib117","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib118","doi-asserted-by":"crossref","DOI":"10.1111\/exd.14389","article-title":"Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease [e-pub ahead of print]","author":"Sims","year":"2021","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib119","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1001\/jamadermatol.2019.2613","article-title":"Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab","volume":"155","author":"Soria","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib120","doi-asserted-by":"crossref","first-page":"e612","DOI":"10.1111\/jdv.16493","article-title":"Alopecia areata development in atopic dermatitis patients treated with dupilumab","volume":"34","author":"St\u00e4nder","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2021.100042_bib121","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jaad.2019.03.020","article-title":"Variable impact of dupilumab on patch testing results and allergic contact dermatitis in adults with atopic dermatitis","volume":"81","author":"Stout","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib122","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jdcr.2018.08.027","article-title":"The role of expanded series patch testing in identifying causality of residual facial dermatitis following initiation of dupilumab therapy","volume":"4","author":"Suresh","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.xjidi.2021.100042_bib123","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/bjd.17629","article-title":"Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real-life practice","volume":"180","author":"Tauber","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib124","first-page":"2684","article-title":"Efficacy of dupilumab on different phenotypes of atopic dermatitis: one-year experience of 221 patients","volume":"9","author":"Tavecchio","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.xjidi.2021.100042_bib125","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2021.100042_bib126","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jdermsci.2019.02.002","article-title":"Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 AND LIBERTY AD SOLO 2)","volume":"94","author":"Tha\u00e7i","year":"2019","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.xjidi.2021.100042_bib127","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2017.03.003","article-title":"Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis","volume":"77","author":"Thyssen","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib128","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/jdv.16724","article-title":"Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study","volume":"35","author":"Touhouche","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2021.100042_bib129","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","article-title":"Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"154","author":"Treister","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib130","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaad.2020.05.102","article-title":"One-year real-world clinical effectiveness, safety, and laboratory safety of dupilumab in Japanese adult patients with atopic dermatitis: a single-center retrospective study","volume":"84","author":"Uchida","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib131","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.18163","article-title":"Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study","volume":"181","author":"Uchida","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib132","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jaad.2019.12.039","article-title":"Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world setting","volume":"82","author":"Uchida","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib133","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jtos.2020.05.008","article-title":"Ocular surface disease associated with dupilumab treatment for atopic diseases","volume":"19","author":"Utine","year":"2021","journal-title":"Ocul Surf"},{"key":"10.1016\/j.xjidi.2021.100042_bib134","first-page":"303","article-title":"Dupilumab-associated blepharoconjunctivitis with giant papillae","volume":"13","author":"Vingopoulos","year":"2020","journal-title":"Int Med Case Rep J"},{"key":"10.1016\/j.xjidi.2021.100042_bib135","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jaad.2019.06.026","article-title":"Characterizing dupilumab facial redness: a multi-institution retrospective medical record review","volume":"82","author":"Waldman","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib136","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/ijd.14573","article-title":"Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records","volume":"59","author":"Wang","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib137","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2021.100042_bib138","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2021.100042_bib139","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/bjd.18031","article-title":"Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series","volume":"181","author":"Willsmore","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib140","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1111\/jdv.15755","article-title":"Pathomechanism of dupilumab-associated inflammatory eye symptoms","volume":"33","author":"Wohlrab","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.xjidi.2021.100042_bib141","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/bjd.18434","article-title":"Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD\u00a0SOLO 2, LIBERTY AD CHRONOS)","volume":"182","author":"Wollenberg","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib142","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","article-title":"Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial","volume":"156","author":"Worm","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib143","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/01676830.2018.1553190","article-title":"Two differing presentations of periocular dermatitis as a side effect of dupilumab for atopic dermatitis","volume":"38","author":"Yamane","year":"2019","journal-title":"Orbit"},{"key":"10.1016\/j.xjidi.2021.100042_bib144","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/ijd.15183","article-title":"Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis","volume":"60","author":"Yamauchi","year":"2021","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.xjidi.2021.100042_bib145","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.cellimm.2015.03.002","article-title":"Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products","volume":"295","author":"Yin","year":"2015","journal-title":"Cell Immunol"},{"key":"10.1016\/j.xjidi.2021.100042_bib146","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1001\/jamadermatol.2019.0109","article-title":"Assessment of the development of new regional dermatoses in patients treated for atopic dermatitis with dupilumab","volume":"155","author":"Zhu","year":"2019","journal-title":"JAMA Dermatol"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026721000436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026721000436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T08:03:21Z","timestamp":1763021001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026721000436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":146,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S2667026721000436"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2021.100042","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2021.100042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100042"}}